Subscribe To
PROF / Profound Medical: TULSA-PRO Now Selling, Recurring Revenues Up 43%
![Profound Medical: TULSA-PRO Now Selling, Recurring Revenues Up 43%](https://cdn.snapi.dev/images/v1/y/p/image-668600179-1943602.jpg)
PROF News
![Profound Medical Corp. (PROF) Q3 2023 Earnings Call Transcript Profound Medical Corp. (PROF) Q3 2023 Earnings Call Transcript](https://cdn.snapi.dev/images/v1/p/j/transcript24-2140536.jpg)
By Seeking Alpha
November 4, 2023
Profound Medical Corp. (PROF) Q3 2023 Earnings Call Transcript
Profound Medical Corp. (NASDAQ:PROF ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Stephen Kilmer - IR Arun Menaw more_horizontal
![Profound Medical to Release Third Quarter 2023 Financial Results on November 2 – Conference Call to Follow Profound Medical to Release Third Quarter 2023 Financial Results on November 2 – Conference Call to Follow](https://cdn.snapi.dev/images/v1/p/t/conf7-2112324.jpg)
By GlobeNewsWire
October 19, 2023
Profound Medical to Release Third Quarter 2023 Financial Results on November 2 – Conference Call to Follow
TORONTO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage med more_horizontal
![Profound Medical to Participate in the 2023 Cantor Global Healthcare Conference Profound Medical to Participate in the 2023 Cantor Global Healthcare Conference](https://cdn.snapi.dev/images/v1/k/2/conf9-2070141.jpg)
By GlobeNewsWire
September 19, 2023
Profound Medical to Participate in the 2023 Cantor Global Healthcare Conference
TORONTO, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage me more_horizontal
![Strength Seen in Profound Medical (PROF): Can Its 19.5% Jump Turn into More Strength? Strength Seen in Profound Medical (PROF): Can Its 19.5% Jump Turn into More Strength?](https://cdn.snapi.dev/images/v1/y/f/default305-2069945.jpg)
By Zacks Investment Research
September 19, 2023
Strength Seen in Profound Medical (PROF): Can Its 19.5% Jump Turn into More Strength?
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions more_horizontal
![Profound Medical Corp. (PROF) Q2 2023 Earnings Call Transcript Profound Medical Corp. (PROF) Q2 2023 Earnings Call Transcript](https://cdn.snapi.dev/images/v1/q/d/transcript17-2016456.jpg)
By Seeking Alpha
August 9, 2023
Profound Medical Corp. (PROF) Q2 2023 Earnings Call Transcript
Profound Medical Corp. (NASDAQ:PROF ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Stephen Kilmer - IR Arun Menawat more_horizontal
![Profound Medical (PROF) Reports Q2 Loss, Misses Revenue Estimates Profound Medical (PROF) Reports Q2 Loss, Misses Revenue Estimates](https://cdn.snapi.dev/images/v1/l/p/default28-2016355.jpg)
By Zacks Investment Research
August 9, 2023
Profound Medical (PROF) Reports Q2 Loss, Misses Revenue Estimates
Profound Medical (PROF) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to los more_horizontal
![Profound Medical to Release Second Quarter 2023 Financial Results on August 9 – Conference Call to Follow Profound Medical to Release Second Quarter 2023 Financial Results on August 9 – Conference Call to Follow](https://cdn.snapi.dev/images/v1/m/g/conf16-2002697.jpg)
By GlobeNewsWire
August 2, 2023
Profound Medical to Release Second Quarter 2023 Financial Results on August 9 – Conference Call to Follow
TORONTO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage med more_horizontal
![Profound Medical: TULSA-PRO Now Selling, Recurring Revenues Up 43% Profound Medical: TULSA-PRO Now Selling, Recurring Revenues Up 43%](https://cdn.snapi.dev/images/v1/y/p/image-668600179-1943602.jpg)
By Seeking Alpha
June 22, 2023
Profound Medical: TULSA-PRO Now Selling, Recurring Revenues Up 43%
Profound Medical Corp's TULSA-PRO system has the potential to disrupt the surgical treatment of prostate disease. The company is delivering solid grow more_horizontal